Last edition
News about "Blood cancer treatment"
Australia Approves First-in-Class Niktimvo for Chronic GVHD Treatment
Niktimvo approval marks a major breakthrough in treating chronic GVHD, introducing a first-in-class targeted therapy for patients with limited treatment options and high unmet medical need.
Blood Cancer Treatment | 05/05/2026 | By News Bureau
Amgen Acquires UK- based Dark Blue Therapeutics in 840M USD Deal
Amgen’s acquisition of Dark Blue Therapeutics, adds a first-in-class protein degrader programme targeting MLLT1/3-driven acute myeloid leukemia to strengthen its early-stage oncology pipeline.<br />
Blood Cancer Treatment | 07/01/2026 | By News Bureau | 120
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy